- $348.60m
- $266.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.35 | ||
| Price to Tang. Book | 4.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.18% | ||
| Return on Equity | -70.17% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.13 | 0.13 | 0.13 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- June 6th, 2003
- Public Since
- July 27th, 2021
- No. of Shareholders
- 62
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 54,898,303
- Address
- 117 Kendrick Street,, Suite 450, NEEDHAM, 02494
- Web
- https://www.candeltx.com/
- Phone
- +1 6179165445
- Auditors
- KPMG LLP
Upcoming Events for CADL
Q4 2025 Candel Therapeutics Inc Earnings Release
Q1 2026 Candel Therapeutics Inc Earnings Release
Q1 2026 Candel Therapeutics Inc Earnings Release
Similar to CADL
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Candel Therapeutics share price?
As of Today at 18:46 UTC, shares in Candel Therapeutics are trading at $6.35. This share price information is delayed by 15 minutes.
How has the Candel Therapeutics share price performed this year?
Shares in Candel Therapeutics last closed at $6.35 and the price had moved by -35.2% over the past 365 days. In terms of relative price strength the Candel Therapeutics share price has underperformed the S&P500 Index by -42.57% over the past year.
What are the analyst and broker recommendations for Candel Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Candel Therapeutics dividend yield?
Candel Therapeutics does not currently pay a dividend.
Does Candel Therapeutics pay a dividend?
Candel Therapeutics does not currently pay a dividend.
When does Candel Therapeutics next pay dividends?
Candel Therapeutics does not currently pay a dividend.
How do I buy Candel Therapeutics shares?
To buy shares in Candel Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Candel Therapeutics?
As of the previous close price of $6.35, shares in Candel Therapeutics had a market capitalisation of $348.60m.
Where are Candel Therapeutics shares listed?
Here are the trading details for Candel Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CADL
What kind of share is Candel Therapeutics?
Based on an overall assessment of its quality, value and momentum Candel Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Candel Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Candel Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Candel Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +9.38%.
As of the last closing price of $6.35, shares in Candel Therapeutics were trading +11.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Candel Therapeutics PE Ratio?
The Candel Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Candel Therapeutics?
Candel Therapeutics' management team is headed by:
- Paul Manning - CHM
- Paul Tak - PRE
- Estuardo Aguilar- Cordova - CFD
- John Canepa - CFO
- Laura Aguilar - OTH